V. Paul DiMondi, PharmD (he/him/his)

Scientific Communications Director
ViiV Healthcare

Disclosure(s): GSK: Stocks/Bonds (Public Company); ViiV Healthcare: Employee

Paul DiMondi, PharmdD is the Dolutegravir Scientific Communications Director at ViiV Healthcare. Paul received his PharmD from Campbell Univsity in 2011 and praticed as a internal medicine clinical pharmacist as well as serving as an assistant professor of pharmacy practice at Campell University prior to joining ViiV Healthcare in 2023.

Poster(s):

• (P-574) Extrapolating Expected Efficacy, Safety, and Pharmacokinetics (PK) of Dolutegravir/Lamivudine (DTG/3TC) in Pregnant People Living with HIV-1 from Pregnancy Data with Combination DTG and/or 3TC Antiretroviral Therapies
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-576) Real-world Experience with the Two-Drug Regimen Dolutegravir/Lamivudine for the Treatment of HIV-1 among Vulnerable People Living with HIV in Canada: Preliminary Results from a Chart Review Study
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT